Should MannKind Investors Bank on a Partnership?

Biotech company MannKind reported its fourth-quarter results last week, and it looks like the debate over its long-term potential will continue until the company releases the trial results for its ultra-rapid insulin, Afrezza. In the company's latest conference call, however, there were questions related to future partnerships.

Could there be a collaboration on the horizon for this biotech, or should investors resist getting their hopes up for the time being? Health care analyst Max Macaluso discusses this topic in the following video.


The future of MannKind?
Will MannKind's disruptive technology revolutionize the way diabetes is treated around the world -- or will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more -- and get a full year of free updates -- click here to grab your copy today.

The article Should MannKind Investors Bank on a Partnership? originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Learn about investing from the comfort of your own home.

Portfolio Basics

Take the first steps to building your portfolio.

View Course »

Investment Strategies

Learn the strategies you need to build a winning portfolio

View Course »

Add a Comment

*0 / 3000 Character Maximum